Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1282 • ACR Convergence 2023
Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement
Meliha Kapetanovic¹, Olivia Olsson², Jon Einarsson¹, Morteza Najibi³ and Ellen Tufvesson⁴, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Lund University, Faculty of Medicine, Lund, Sweden, ³Lund University, Institution for clinical sciences, section for rheumatology Lund, Lund, Sweden, ⁴Lund University, Institution for clinical scienses, section for lung medicine and allergy, Lund, Sweden
Background/Purpose: Rheumatoid arthritis (RA) related lung manifestations have a significantly impact the morbidity and mortality. Male gender and RF/ACPA positivity are known risk factors but…
Abstract Number: 1298 • ACR Convergence 2023
Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice
Fiona Oudart¹, Marion THOMAS², Alice Combier³, Anna Molto², Yannick ALLANORE⁴ and Jérôme Avouac⁵, ¹Université Paris Cité, Paris, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³APHP / Cochin Hospital, Paris, France, ⁴Université Paris Cité, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Increased risk of venous thromboembolism (VTE) has been reported in rheumatoid arthritis (RA) compared to the general population. However, factors associated with the risk…
Abstract Number: 1314 • ACR Convergence 2023
Safety Results from a Phase 1 Double-blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early RA
Nora Singer¹, Maya Breitman², Maricela Haghiac², Larraine Gordesky³, Jane Reese⁴, Steven Lewis², Emma Barnboym², Noor Hussein⁵, Susan Lasalvia⁶, Elizabeth Mellins⁷, Tracey Bonfield⁸, Donald Anthony⁹, Arnold Caplan¹⁰ and Hillard Lazarus⁸, ¹The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ²The MetroHealth System at CWRU, Cleveland, OH, ³The MetroHealth System at CWRU and Louis Stokes Cleveland VA, Cleveland, OH, ⁴CWRU, University Hospitals of Cleveland, Cleveland, OH, ⁵Stanford University, Palo Alta, CA, ⁶The MetroHealth System, Cleveland, OH, ⁷Stanford University, Stanford, CA, ⁸CWRU and University Hospitals of Cleveland, Cleveland, OH, ⁹Case Western Reserve University, Cleveland VA Medical Center, The MetroHealth System, Cleveland, OH, ¹⁰CWRU, Center for Skeletal Biology, Cleveland, OH
Background/Purpose: The purpose of this study was to evaluate the safety of bone-marrow derived allogeneic mesenchymal stem cells (MSCs) as therapeutic agents in early rheumatoid…
Abstract Number: 1331 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Franktien Turkstra², Jos W.R. Twisk¹, Maarten Boers¹, Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
Abstract Number: 1677 • ACR Convergence 2023
Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
Abhishek Abhishek¹, Nicholas Peckham², Corinna Pade³, Joseph Gibbons³, Lucy Cureton², Anne Francis², Vicki Barber², Jennifer Williams², duncan Appelbe², lucy Eldridge², patrick Julier², daniel Altmann⁴, James Bluett⁵, Tim Brooks⁶, Laura Coates², ines Rombach⁷, Amanda Semper⁶, Ashley Otter⁶, Ana Valdes¹, Jonathan Nguyen-Van-Tam¹, Hywel Williams¹, Aine McKnight³, Rosemary Boyton⁴ and jonathan Cook², ¹University of Nottingham, Nottingham, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴Imperial College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶UK Health Security Agency, Porton Down, United Kingdom, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Immunosuppressive treatments inhibit vaccine-induced immunity. We evaluated if a two-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein…
Abstract Number: 1732 • ACR Convergence 2023
Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA)
Huiyi Wang¹, Kangkang Luo¹, Shuxin Xu¹, Jiayin Zhou¹, Santi Chen², Jun wang², Wenzhao Li², Jing Zhao¹ and Cunxiang Ju¹, ¹GemPharmatech CO., Ltd., Nanjing, China, ²GemPharmatech LLC, La Jolla, CA
Background/Purpose: The differences between human and mouse immune systems make it challenging to accurately reflect the immunopathogenesis of autoimmune diseases in patients. Therefore, translational research…
Abstract Number: 1748 • ACR Convergence 2023
Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies
S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Breanna Butler¹, Jill Poole¹, Michael Duryee¹, Nozima Aripova¹, Carlos Hunter¹, Bridget Kramer¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…
Abstract Number: 1912 • ACR Convergence 2023
Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System
Khashayar Ahmadmehrabi¹, Navin Ravishankar², Diana Mekhiel³ and Zineb Aouhab³, ¹Loyola University Medical Center, Oak Park, IL, ²Indiana University Health, Indianapolis, IN, ³Loyola University Medical Center, Maywood, IL
Background/Purpose: Given the progressive joint damage and physical disability associated with uncontrolled Rheumatoid arthritis (RA), a treat-to target-strategy through the early utilization of disease-modifying antirheumatic…
Abstract Number: 2101 • ACR Convergence 2023
Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
Yusuke Miwa¹, Yuko Miwa-mitamura², Hiroi Tomioka³ and Michio Hosaka⁴, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Tokyo, Japan, ³Department of Psychiatry, School of Medicine, Showa University, Yokohama, Japan, ⁴Department of psychosomatic medicine, Katsuyama Clinic, Fujikawaguchiko, Japan
Background/Purpose: It has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods.…
Abstract Number: 2118 • ACR Convergence 2023
New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry
Robert Spandorfer¹, Kevin Kane², George Reed², Dimitrios Pappas², Joel Kremer², Jeffrey Curtis³ and Iris Navarro-Millán⁴, ¹Hospital for Special Surgery, Brooklyn, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
Abstract Number: 2134 • ACR Convergence 2023
Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA
Monica Leu Agelii¹, Outi Sareila², Erik Lönnblom², Kristina Forslind³, Maria Andersson³, Alf Kastbom⁴, Christopher Sjöwall⁵, Lennart Jacobsson⁶, Jan Kihlberg⁷, Rikard Holmdahl², Ingiäld Hafström² and Inger Gjertsson⁸, ¹Gothenburg University, Goteborg, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³FoU Spenshult, Halmstad, Sweden, ⁴Linköping University, Linköping, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶University of Gothenburg, Malmö, Sweden, ⁷Uppsala University, Uppsala, Sweden, ⁸Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: One of the major challenges in the management of rheumatoid arthritis (RA) is to determine individual treatment and predict the prognosis. On a group…
Abstract Number: 2150 • ACR Convergence 2023
Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients
Yuriko Yamamura¹, Valerie Corrigall², Lara Ravanetti³, Jorge De Alba³, Roly Foulkes⁴, Paul Eggleton⁵ and Carl Goodyear⁶, ¹School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, ²Revolo Biotherapeutics, Tadworth, United Kingdom, ³Revolo Biotherapeutics, London, United Kingdom, ⁴Revolo Biotherapeutics, Slough, United Kingdom, ⁵Revolo Biotherapeutics, Exeter, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In Rheumatoid arthritis (RA), osteoclasts derived from CD14+ Monocytes are associated with a risk of progressive bone and joint destruction, which fundamentally impacts quality-of-life.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].